Search

Displaying results 3511 - 3520 of 10000 in total
  1. Drug

    Fluoroazomycin arabinoside F-18

    go.drugbank.com/drugs/DB15134
    Investigational

    Fluoroazomycin arabinoside F-18 is under investigation in clinical trial NCT03257150 (A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer).

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Indium In-111 oxyquinoline

    go.drugbank.com/drugs/DB09473
    Approved

    It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. … It is therefore useful in nuclear medicine, and is used in the labeling of leukocytes for localization of processes to which leukocytes migrate, such as those associated with abscesses or other infections

    Synonyms: In-111 oxyquinoline, Indium In-111 oxineProducts: Indium In 111 Oxyquinoline, Indium in 111 Oxyquinoline
  3. Drug

    Niflumic acid

    go.drugbank.com/drugs/DB04552
    Investigational

    Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

  4. Drug

    Diacerein

    go.drugbank.com/drugs/DB11994
    ApprovedInvestigationalWithdrawn

    It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea [L780].

  5. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.

  6. Drug

    Sitamaquine

    go.drugbank.com/drugs/DB04909
    Investigational

    Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential

  7. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.

  8. Drug

    Midomafetamine

    go.drugbank.com/drugs/DB01454
    IllicitInvestigational

    An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. … It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

  9. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.

  10. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its … Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations.